. Author manuscript; available in PMC: 2010 Jan 1.

Published in final edited form as: Mol Pharm. 2009;6(1):246–254. doi: 10.1021/mp8001528

Table 2.

Liver metastases in LLC tumor-bearing mice (at a, b; P≤0.05)

Treatment	Relative liver weight (%)	Number of liver metastatic foci	% of metastases ( no. mice with metastases/gp)
PBS control	5.1±0.12	52±17^a,b	60% (6/10)
Doxil^®	4.94±0.07	33±10.5^a	22% (2/9)
mAb 2C5-modified Doxil^®	4.76±0.05	18^b	11% (1/9)